Budeflam 0,125 Mg/Ml, 0,25 Mg/Ml & 0,5 Mg/Ml Respules 0,125 mg; 0,25mg & 0,5 mg Nebuliser Suspension
PDF Leaflet Revision Date: Not applicable
Clinical Summary
Quick overview from the medicine insert
Indication
Management of asthma and acute laryngotracheobronchitis-croup.
Dosage (summary)
Adults: 0.5 to 1 mg twice daily; Children: 0.25 to 1 mg twice daily depending on previous therapy.
Onset of Action / Duration
Onset: 10 days, Duration: Individualized.
Special Populations
- Children under 12 months
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy and breastfeeding not established; prefer inhaled over oral glucocorticosteroids.
Key Drug Interactions
- CYP3A inhibitors (e.g., ketoconazole, itraconazole)
Contraindications
- Hypersensitivity to budesonide
- Active tuberculosis
- Fungal/viral infections in airways
Common side effects
- Oropharyngeal candidiasis
- Pneumonia in COPD patients
- Hoarseness
- Cough
Counselling Points
- Rinse mouth after use
- Monitor for signs of adrenal insufficiency
- Avoid use in acute asthma episodes
Serious warnings
- Paradoxical bronchospasm
- Adrenal suppression
- Growth retardation in children
Important Disclaimer
The Budeflam 0,125 Mg/Ml, 0,25 Mg/Ml & 0,5 Mg/Ml Respules 0,125 mg; 0,25mg & 0,5 mg Nebuliser Suspension professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
